MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program at the World Asthma Meeting at the Lutfi Kirdar Convention and Exhibition Center in Istanbul, Turkey.
The oral and poster presentation entitled, "Efficacy and safety of a novel submicron particle formulation of budesonide for nebulized delivery in a 6 week study in 1-18 year old asthmatic children" will be presented on Monday, June 25th at 4:30pm local time.
In addition, the Company has a second poster presentation available for viewing at the conference. The second poster entitled, "Safety, tolerability, and pharmacokinetics of a novel submicron particle formulation of nebulized budesonide for the treatment of asthma" will be presented on Saturday, June 23rd at 4:30pm local time.
Unit Dose Budesonide is the Company's proprietary nebulized version of budesonide intended to treat pediatric asthma in children from six months to eight years of age. UDB is designed to be administered more quickly and to provide efficacy at lower doses than conventional nebulized budesonide, which is the current leading treatment for pediatric asthma. Potential faster delivery and efficacy at a lower dose together may offer improved safety, compliance and convenience for young patients who suffer from asthma.
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, email@example.com
Web site: http://www.mappharma.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2007